Alvotech Announces June FDA Resubmissions, But Execution Risk Remains High

What happened

Alvotech plans to resubmit three BLAs to the FDA in June, addressing manufacturing observations that led to previous complete response letters, with management hoping for approvals by year-end. This timeline provides a clearer catalyst than before, but the company's single-site Reykjavik facility has a history of repeated FDA deficiencies that have delayed multiple products. The DeepValue report assigns a WAIT rating with a base case of $5.75, reflecting skepticism that remediation will be quick or durable given prior setbacks and material internal control weaknesses. The market has already priced in significant regulatory risk, with the stock down 65% over the past year to ~$4.62. While a successful resubmission could drive a near-term re-rating, the execution trajectory remains uncertain and the balance sheet is highly leveraged with ~$1.1B in debt and negative equity.

Implication

The June resubmission introduces a near-term catalyst that could reduce uncertainty if the FDA clears the applications, potentially driving the stock toward the base case of $5.75. However, the DeepValue report highlights that past FDA deficiencies and weak internal controls make a smooth approval far from certain, and the bear case of $3.00 remains plausible if remediation fails or another CRL emerges. The high debt load and negative equity mean that any setback could trigger severe dilution or restructuring. Investors should monitor for tangible signs of FDA facility reinspection and positive progress on AVT05 rather than relying on management timelines. Given the asymmetric downside, a disciplined approach would be to wait for evidence of sustainable compliance before building a position, or to set a strict entry price near $3.75 for a more attractive risk-reward.

Thesis delta

The news provides a specific resubmission timeline, which is a step forward from the vague remediation language in the DeepValue report. However, the core thesis remains unchanged: Alvotech must prove it can consistently manufacture to FDA standards, and the balanced risk-reward still favors waiting for evidence of durable compliance before committing capital.